Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | Journal of Inflammation

Fig. 1

From: Anti-vascular endothelial growth factor agent reduces inflammation in macular edema with central retinal vein occlusion

Fig. 1

Aqueous flare value at 1 and 6 months after intravitreal ranibizumab injection (IRI) and at the 1st recurrence of macular edema. The aqueous flare value was significantly lower than the baseline value (13.5 ± 7.1photon counts/ms) at (a) 1 month after IRI (8.7 ± 3.6 photon counts/ms) and at (b) 6 months after IRI (8.6 ± 3.4 photon counts/ms) (P < 0.001 and P = 0.003, respectively). c In the 16 patients with recurrence, the aqueous flare value was significantly higher at the 1st recurrence (12.2 ± 5.3 photon counts/ms) compared with before recurrence (8.4 ± 3.0 photon counts/ms, P < 0.001)

Back to article page

Journal of Inflammation

ISSN: 1476-9255

Contact us